Veterinary Medicines

Carporal VET. 160 mg tablets for dogs

Authorised
  • Carprofen
Download as PDF

Product identification

Medicine name:
Carporal VET. 160 mg tablets for dogs
Canicaral vet, 160 mg tabletid koertele
Active substance:
  • Carprofen
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Carprofen
    160.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AE91
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:
  • Cardboard box of 9 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 8 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 5 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 4 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 3 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 7 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 6 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 50 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 1 blister (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 2 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 10 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets
  • Cardboard box of 25 blisters (Aluminium - PA/ALU/PVC blister) of 10 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Le Vet. Beheer B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Artesan Pharma GmbH & Co. KG
  • Lelypharma B.V.
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 1921
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0191/002
Concerned member states:
  • Austria
  • Belgium
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 29/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."